Silencing of ocular transthyretin, a gene responsible for hereditary transthyretin amyloidosis, by intravitreal injection of an siRNA conjugate into rabbit eyes.

Electroretinogram Hereditary transthyretin amyloidosis Intravitreal injection Ocular amyloidosis siRNA conjugate siRNA therapeutic

Journal

Biochemical and biophysical research communications
ISSN: 1090-2104
Titre abrégé: Biochem Biophys Res Commun
Pays: United States
ID NLM: 0372516

Informations de publication

Date de publication:
16 Dec 2023
Historique:
received: 12 11 2023
revised: 10 12 2023
accepted: 15 12 2023
medline: 2 1 2024
pubmed: 2 1 2024
entrez: 29 12 2023
Statut: aheadofprint

Résumé

The first small interfering RNA (siRNA) therapeutic received approval for hereditary transthyretin (ATTRv) amyloidosis, and the patients' lifespan extension by specific inhibition of hepatic synthesis of transthyretin (TTR) is expected. However, ocular amyloidosis in these patients has been a crucial issue. This study aims to evaluate the efficacy and safety of intravitreal TTR siRNA conjugate injection into rabbit eyes. Rabbit (r) TTR siRNA is a screened TTR siRNA conjugate from 53 candidates. The intraocular pressure (IOP) immediately after injection was high despite the 65.9 % decrease of aqueous humor TTR protein levels in the rTTR siRNA group compared with those in the Control siRNA group 2 weeks after the 50 μL siRNA injection. The IOP spike was milder after the 30 μL siRNA injection, and aqueous humor TTR levels decreased by ∼50 % in the rTTR siRNA group, which is consistent with the mRNA levels in the retina. The parameters of dark-adapted, light-adapted, and light-adapted 30 Hz electroretinogram and the thickness of each retinal layer in histological analysis demonstrated no significant differences between the groups. In conclusion, we developed TTR siRNA conjugates for rabbit eyes, and the results indicate that intravitreal TTR siRNA conjugate injection could be a therapeutic option for ocular amyloidosis caused by ATTRv amyloidosis.

Identifiants

pubmed: 38157582
pii: S0006-291X(23)01491-2
doi: 10.1016/j.bbrc.2023.149397
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

149397

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Assoc. Prof. Hirofumi Jono reports equipment, drugs, or supplies was provided by Alnylam Pharmaceuticals. Prof. Mitsuharu Ueda reports a relationship with Alnylam Pharmaceuticals and Pfizer Inc. that includes: funding grants. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Takahiro Watanabe (T)

Department of Ophthalmology, Faculty of Life Sciences, Kumamoto University, Kumamoto, 860-8556, Japan.

Yuji Takihara (Y)

Department of Ophthalmology, Faculty of Life Sciences, Kumamoto University, Kumamoto, 860-8556, Japan. Electronic address: ytakihara@kumamoto-u.ac.jp.

Hirofumi Jono (H)

Department of Pharmacy, Kumamoto University Hospital, Kumamoto, 860-8556, Japan; Department of Clinical Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, 860-8556, Japan.

Tomokazu Fujimoto (T)

Department of Ophthalmology, Faculty of Life Sciences, Kumamoto University, Kumamoto, 860-8556, Japan.

Masayoshi Tasaki (M)

Department of Neurology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, 860-0811, Japan; Department of Biomedical Laboratory Sciences, Graduate School of Health Sciences, Kumamoto University, Kumamoto, 862-0976, Japan.

Aito Isoguchi (A)

Department of Neurology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, 860-0811, Japan.

Yui Urahashi (Y)

Department of Ophthalmology, Faculty of Life Sciences, Kumamoto University, Kumamoto, 860-8556, Japan.

Takefumi Shimoda (T)

Department of Ophthalmology, Faculty of Life Sciences, Kumamoto University, Kumamoto, 860-8556, Japan.

Eri Takahashi (E)

Department of Ophthalmology, Faculty of Life Sciences, Kumamoto University, Kumamoto, 860-8556, Japan.

Yukio Ando (Y)

Department of Amyloidosis Research, Faculty of Pharmaceutical Sciences, Nagasaki International University, Sasebo, 859-3298, Japan.

Shinji Ueno (S)

Department of Ophthalmology, Hirosaki University Graduate School of Medicine, Hirosaki, 036-8562, Japan.

Mitsuharu Ueda (M)

Department of Neurology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, 860-0811, Japan.

Toshihiro Inoue (T)

Department of Ophthalmology, Faculty of Life Sciences, Kumamoto University, Kumamoto, 860-8556, Japan.

Classifications MeSH